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Most of the high yielding transient gene expression (TGE) methods for CHO cells reported in the literature 
involve extensive cell line engineering and plasmid vector optimization in addition to long fed batch cultures 
lasting up to 21 days. However, this is a laborious, time intensive process and also requires specific vector 
engineering for transient expression. Here, we present results from development of a high titer TGE process 
based on GS-CHO cells without resorting to host cell line engineering or TGE specific vector engineering. This 
was achieved by optimization of direct addition of DNA and PEI, use of DMA to enhance transgene mRNA 
levels and addition of a proprietary feeds. Protein titers of up to 0.35 g/L or 1 g/L were reached in a 7 day or a 
16 day bioprocess respectively. Robustness and reproducibility of this method was demonstrated at scales 
ranging from 2 ml to 2 L. Moreover, these transfections could be performed in a high throughput manner in 24 
deep well plates. Taking advantage of this, we coupled this high throughput transfection process to a high-
throughput semi-automated Protein A purification process capable of purifying up to 72 unique mAbs 
simultaneously. We designed a variable volume elution strategy based on supernatant titer and were able to 
obtain protein yields of 0.25 mg to 1 mg at concentration >0.5 mg/ml. In efforts to further increase protein 
expression levels, we tested co-transfection of proteins involved in the unfolded protein response with the goal 
to enhance secretion capabilities of the transfected cell population. We identified that co-transfection of plasmid 
DNA encoding XBP1S increased protein expression by 15% to 80%. We also present case studies comparing 
product quality attributes from transient HEK293, transient CHO and stable CHO pool. Overall, our results 
demonstrate that a high yielding and representative transient CHO process can be developed while maintaining 
the speed and simplicity of a TGE process.  
